Case number 1:17-cv-01314
Teijin Limited et al v. Aurobindo Pharma Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 8, 2020 | 1 | Complaint (16) |
| Apr 20, 2018 | N/A | Terminated Case (0) Docket Text: CASE CLOSED per DI 20 (cak) |
| Apr 10, 2018 | 20 | SO ORDERED (2) Docket Text: SO ORDERED, re [19] Granting Stipulation of Dismissal filed by Teijin Pharma Limited, Teijin Limited, Takeda Pharmaceuticals U.S.A., Inc.. Signed by Judge Mary Pat Thynge on 4/10/18. (kjk) |
| Apr 9, 2018 | 19 | Stipulation of Dismissal (2) Docket Text: STIPULATION of Dismissal (without prejudice) by Takeda Pharmaceuticals U.S.A., Inc., Teijin Limited, Teijin Pharma Limited. (Blumenfeld, Jack) |
| Mar 19, 2018 | 18 | Redacted Document (3) Docket Text: REDACTED VERSION of [17] Stipulation by Takeda Pharmaceuticals U.S.A., Inc., Teijin Limited, Teijin Pharma Limited. (Blumenfeld, Jack) |
| Mar 15, 2018 | N/A | SO ORDERED (0) |
| Feb 21, 2018 | 16 | Redacted Document (2) Docket Text: REDACTED VERSION of [14] Stipulation by Takeda Pharmaceuticals U.S.A., Inc., Teijin Limited, Teijin Pharma Limited. (Noreika, Maryellen) |
| Feb 16, 2018 | N/A | SO ORDERED (0) |
| Feb 16, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER re [13] Order Setting Teleconference: The teleconference set for 2/23/18 at 11:00 AM with Judge Thynge is cancelled. There is no need for counsel to provide the Proposed Scheduling Order which is due 2/16/18. Ordered by Judge Mary Pat Thynge on 2/16/18. (cak) |
| Feb 5, 2018 | 13 | Order Setting Teleconference (2) Docket Text: ORDER Setting Teleconference: A Rule 16 Scheduling Telephone Conference is set for 2/23/2018 at 11:00 AM Eastern Time before Judge Mary Pat Thynge. SEE ORDER FOR DETAILS. Plaintiffs' counsel to initiate the call. Signed by Judge Mary Pat Thynge on 2/5/18. (cak) |
| Feb 5, 2018 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Steven J. Moore for Aurobindo Pharma USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (nmg) |
| Feb 5, 2018 | N/A | Order on Motion to Appear Pro Hac Vice (0) Docket Text: SO ORDERED granting [12] Motion to Appear Pro Hac Vice of Attorney Steven J. Moore of Withers Bergman LLP - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Signed by Judge Mary Pat Thynge on 2/5/18. (cak) |
| Feb 1, 2018 | 10 | Answer to Complaint (23) Docket Text: ANSWER to [1] Complaint, Affirmative Defenses, COUNTERCLAIM against Takeda Pharmaceuticals U.S.A., Inc., Teijin Limited, Teijin Pharma Limited by Aurobindo Pharma USA Inc., Aurobindo Pharma Ltd..(Connolly, Arthur) |
| Feb 1, 2018 | 11 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Connolly, Arthur) |
| Feb 1, 2018 | 12 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore of Withers Bergman LLP - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. Motions referred to Mary Pat Thynge.(Connolly, Arthur) |
| Dec 21, 2017 | N/A | SO ORDERED (0) |
| Dec 21, 2017 | 9 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to Respond to the Complaint to February 1, 2018 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Connolly, Arthur) |
| Dec 13, 2017 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Teijin Pharma Limited, Teijin Limited, Takeda Pharmaceuticals U.S.A., Inc.. Aurobindo Pharma USA Inc. served on 12/12/2017, answer due 1/2/2018. (Noreika, Maryellen) |
| Dec 13, 2017 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Teijin Pharma Limited, Teijin Limited, Takeda Pharmaceuticals U.S.A., Inc.. Aurobindo Pharma Ltd. served on 12/12/2017, answer due 1/2/2018. (Noreika, Maryellen) |
| Sep 20, 2017 | N/A | Remark (0) Docket Text: ***NOTE: If the parties jointly consent to Chief Magistrate Judge Thynges jurisdiction to conduct all proceedings in this case, then the Pretrial Conference and Trial will be presided over by Judge Thynge consistent with 28 U.S.C. ยง 636. Otherwise, in accordance with the District Court's procedures for "Assignment of Cases to Visiting Judges" (issued May 26, 2017 and available on the District Court's website), upon the filing of a case-dispositive motion (e.g., a motion to dismiss, a motion for judgment on the pleadings, a motion for summary judgment, or initiation of the claim construction process in a patent case), VAC cases will be reassigned to a visiting District Judge, and any further dates in the Scheduling Order, including the Pretrial Conference and Trial dates, may be adjusted dependent on the availability of the visiting District Judge. (cak) |
| Sep 20, 2017 | N/A | Case Referred to Magistrate Judge (0) Docket Text: CASE REFERRED to Magistrate Judge Mary Pat Thynge. (This matter has been assigned to the Vacant Judgeship and referred to a Magistrate Judge for handling through case-dispositive motions. The Magistrate Judge has full authority permitted by law to manage this matter, including entering schedules through trial, deciding non-dispositive matters and making recommendations as to the resolution of dispositive matters. Litigants and counsel are reminded that they have the option of consenting to the Magistrate Judge to handle the case in full, including trial, or consenting to having a particular motion resolved by the Magistrate Judge.) (rjb) |
| Sep 20, 2017 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Vacant Judgeship (2017). Please include initials of VAC after the case number on all documents filed. (rjb) |
| Sep 18, 2017 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma Ltd. on 9/18/2017; Aurobindo Pharma USA Inc. on 9/18/2017. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (jcs) |
| Sep 15, 2017 | 6 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teijin Limited for Teijin Pharma Limited. No Corporate Parent or Affiliate Identified for Teijin Limited. filed by Teijin Limited, Teijin Pharma Limited. (jcs) |
| Sep 15, 2017 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Limited, Corporate Parent Takeda Pharmaceuticals International, AG for Takeda Pharmaceuticals U.S.A., Inc. filed by Takeda Pharmaceuticals U.S.A., Inc. (jcs) |
| Sep 15, 2017 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,225,474 B1; 7,361,676 B2; 8,372,872 B2; 9,107,912 B2. (jcs) |
| Sep 15, 2017 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/7/2017. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 2/7/2020. (jcs) |
| Sep 15, 2017 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) |
| Sep 15, 2017 | 1 | Civil Cover Sheet (2) |
| Sep 15, 2017 | 1 | Exhibit A-H (153) |
| Sep 15, 2017 | 1 | Main Document (16) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT filed against Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2225600.) - filed by Teijin Pharma Limited, Teijin Limited, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: # (1) Exhibit A-H, # (2) Civil Cover Sheet)(jcs) |
| Sep 15, 2017 | 1 | Complaint* (1) |
